2017 Agenda

Day 1

Wednesday 20 September, 2017

08:00
Main Conference Registration and Morning Coffee

08:50
Welcome Address and Ice Breaker from IBC Asia

Opening Keynote Sessions

Pharmacon Asia Opening Plenary Session
Joint Session with Pharmaceutical Market Access, Accelerating Clinical Trials in Asia and Pharmaceutical Regulatory Affairs Asia

09:00
Chairperson’s Opening Remarks

Alex Matter, CEO, Experimental Therapeutics Centre & D3, A*STAR, Singapore

09:10
Keynote
From Trials to Table – The Move Towards a More Patient-Centric Approach 

John Wilbanks, Chief Commons Officer, Sage Bionetworks, Senior Fellow, Ewing Marion Kauffman Foundation and FasterCures, USA
TEDGlobal 2012 Speaker on “Let’s Pool Our Medical Data”

John Wilbanks seeks to transform and innovate in medical research by accelerating data sharing between clinical studies. As the Chief Commons Officer at Sage Bionetworks, he is in-charge of figuring out how to design policies and technologies that allow health and biological data to be broadly shared between patients, clinicians, and data analysts.

Sage Bionetworks has put their open source toolkit innovation to the test by designing an application to conduct a set of Sage Bionetworks mobile research studies enrolling more than 100,000 participants in less than two years and integrated into more than 25 studies outside of Sage, including the US Precision Medicine Initiative

To view John’s talk at TEDGlobal 2012, click here

09:40
Industry Roundtable:
Drug Development, Pricing and Access – Bringing Together the Technical, Regulatory and Economic Considerations  

  • Patient centric drug development and access
  • ROI drivers, and outlook for the clinical research and drug development market
  • Regulatory priorities across the pharma value chain
  • Drug pricing developments
  • Regulatory updates - harmonization, new policy, clarity and speed in licensing, submission and approval
  • What are drug development ROIs looking like, and new partnership models for better harnessing ROIs

Moderator:
Alex Matter, CEO, Experimental Therapeutics Centre & D3, A*STAR, Singapore

Panelists:
Li Ling Liu, Director, Good Registration Management (GRM), Researcher, Deputy Director General Office, Taiwan Food and Drug Administration (TFDA), Taiwan
Eva Kopecna, Senior Director Generics Regulatory Affairs Global OTC, Teva Pharmaceuticals International GmbH, Switzerland 
Qing Xi, Head of Government Affairs, Market Access & Communications, Pfizer, China
Jean-François Baladi, Senior Executive, Health Economics and Market Access, Novartis Pharma K.K., Japan
PJ Chen, Vice President, Head of Medical and Clinical Affairs Centre, United BioPharma, Taiwan

10:30
Morning Networking and Refreshment Break

3rd Annual Pharma Market Access and Pricing Summit Asia Commences
Patient-Centric Approach And Access Strategy

11:10
Chairperson’s Introduction
Jean-Francois Baladi, Senior Executive, Health Economics and Market Access, Novartis Pharma K.K., Japan

11:20
Improving Patient Access and Real-World Outcomes in Asia

  • Patient access challenges and treatment barriers
  • Creative access strategies to increase market reach by removing financial barriers while maintaining price
  • Disease management solutions that improve adherence and compliance to treatment

Speaker: Michael Hofer, Regional Business Development Manager, DKSH, Asia

Co-presenters:
Joseph Saba, Co-Founder and Chief Executive Officer, Axios International
Maryline Marquet
, APAC Managing Director, Human Care Systems (HCS)

11:55
Importance of Patient-Centric Approaches in Defining Access Strategy

  • Why Patient-centric is crucial
  • How can integrate all difference needs into one goal
  • What Access strategy can be defined

Sittipong Liamsuwan, Policy & Market Access Director, MSD (Thailand) Ltd., Thailand

12:30
Networking Lunch

13:30
A Patient-Centric Model for Access to Unregistered Therapeutic Products

  • Today’s challenges in drug development and access to pre-approval medicines
  • A digital access model for patients with unmet medical needs globally
  • Real-world evidence to improve healthcare decision making for all stakeholders
  • Turn-key solution for Asian drug developers to bring medical innovations to the rest of the world

Robert Kraal, Chief Operations Officer, myTomorrows, Netherlands

14:00
Translating Rare Disease Therapies for Improved Patient Care and Outcomes

  • Examining the challenges of bringing rare disease therapies to market, and its impact on patients
  • Navigating complex regulatory and policy environments, to ensure patient access
  • Communication strategies, advocacy and partnering for rare disease treatments

Cameron Milliner, Head Public Affairs and Patient Advocacy - APAC, Shire, Singapore

A New Thinking On Pricing And Reimbursement

14:30
Case study: Innovative Pricing Strategies for Expensive Therapeutics or Drugs

  • Budget and Reimbursement for expensive therapeutics in Korea
  • Reimbursement policies to enable the product launching of costly drugs/ treatment
  • Improved access and pitfalls to market and patient to ensure the economic outcome
  • Strategies of market access in South Korea

Megan Kim, Head of Market Access Korea, Boehringer Ingelheim Pte Ltd, Korea

15:00
Implementation of Integrated Market Access Strategy for Negotiation of Better Pricing and Reimbursement

  • Formulating a Market Access Strategy with real-world data
  • Aligning your data to evidence requirements in HTA markets
  • Usage of evidence for pricing and reimbursement negotiations

Chris King, Real-World Insights Principal, QuintilesIMS, Singapore

15:30
Afternoon Networking & Refreshment Break

16:00 
Taiwan’s Reimbursement Model and Drug Price Review

  • Taiwan's healthcare system, national insurance program and getting market access
  • Reimbursement and pricing approval process
  • Timelines
  • Health Technology Assessments (HTA) on new drugs
  • Pricing recommendations by Drug Benefit Committee 

Yi-Chieh Lin, Officer, Medical Review and Pharmaceutical Benefits Division, National Health Insurance Administration, Ministry of Health and Welfare, Taiwan

16:30
Impact of Drug Price Review in Japan -- Opportunities and Challenges for Drug Pricing & Reimbursement

  • Current outlook of Japan’s healthcare pricing & reimbursement reform and future impact
  • Key ingredients for future success - The win-win situation for government and pharma companies
  • Innovative pricing and reimbursement strategies after implementation of pricing reforms
  • The role of outcome research and pharmacoeconomic evaluations post pricing and healthcare reform

Jean-François Baladi, Senior Executive, Health Economics and Market Access, Novartis Pharma K.K., Japan

17:00
A Strong Pricing Strategy for Universal Health Coverage in Indonesia

  • Examining the overall healthcare and current reimbursement situation in Indonesia
  • Overcoming the challenges for Indonesia’s road to Universal Health Coverage
  • Key pricing strategies to understand and undertake for successful UHC

Rosalina Saleh, Market Access Lead, PT Boehringer Ingelheim Indonesia

17:30
Chairperson’s Summary and End of Main Conference Day One

Networking Cocktail

 

Day 2

Thursday 21 September, 2017

09:00
Chairperson’s Opening Remarks
Qing Xi
, Head of Government Affairs, Market Access & Communications, Pfizer, China

Growth Markets And Strategy Spotlight

09:10
HTA is Japan – Where Are We Now, and Where Are We Going?

  • A look at what we know and what we don’t know about Japan’s HTA
  • A discussion on where we think HTA is heading, and what it could potentially mean for manufacturers

Neal Somchand, Senior Consultant, Deallus Consulting, Japan

09:40
[Philippines Market]
Embracing the Challenges of Implementing Universal Health Coverage and Pharma Market Access in the Philippines

  • Mitigation of high out-of-pocket expense in health care due to costly medicine
  • Benefits and risks to look out for while implementing pharma market access
  • Leveraging the proven solutions to improve access – What has been done and challenges remain ahead?
  • Exploring more innovative market access strategies in public and private sectors

Enrique A. Tayag, Assistant Secretary, Office for Policy and Health Systems, Department of Health, Philippines

10:10
Morning Networking and Refreshment Break

10:40
[Indonesia Spotlights]
How to Integrate Market Access Internally and Externally in Indonesia?

  • Examining the current public immunization policy landscape within Indonesia
  • Sustaining and driving policies through effective advocacy strategies and broad internal and external engagements to maximize immunization benefit
  • Achieving better market access for business growth, sustainability and public healthcare

Farida Malawi, Head of Public Sales and New Channels, Vaccine Policy & Advocacy and Market Access, Sanofi Pasteur, Indonesia

11:10
[Malaysia Outlook]
Strategies to Integrate Pharma Market Access in Malaysia

  • Market access environment in Malaysia
  • Challenges in market access for innovative medicines in Malaysia
  • Strategies in consideration that may improve access to innovative medicines

Nathan Kothandaraman, Lead, Market Access, Johnson & Johnson Sdn Bhd, Malaysia

11:40
[China Case Study]
Innovative Strategies to Integrate Market Access Internally and Externally in China

  • The overall healthcare and reimbursement investment/situation in China
  • Current pharma market access environment and future trend in China
  • Key challenges and opportunities for MNC pharma companies
  • Suggested strategies  

Qing Xi, Head of Government Affairs, Market Access & Communications, Pfizer, China

12:10
Networking Lunch

Leveraging Heor And Rwe To Enhance Market Entry

13:10
Leveraging RWE for Market Access in Asia-Pacific

  • Growing interest of RWE in Asia-Pacific
  • Leveraging RWE for Market Access strategies
  • Challenges and opportunities in the region

Anh Bourcet, Associate Director, ASPAC Health Economic & Market Access, Orthopedics, Johnson & Johnson, Singapore

13:40
Connecting with Patients through Digital Data Collection to Support HEOR

  • Collaborating with patients on digital health projects
  • Digital data collection to control costs
  • Digital data collection to transform the patient journey

Colette Hamilton, Chief Operating Officer, RWE Genesys, United Kingdom

14:10
Are We Ready for a Cure? - Key Value Demonstration and Policy Considerations for the New Wave of Regenerative Medicines~ Industry Perspective

  • What does the emerging regenerative therapies landscape look like?
  • What does this mean for patients with unmet needs?
  • Opportunity to shape new value based reimbursement

Tay Salimullah, Global Strategic Projects Leader, Real World Evidence, Novartis Pharma AG, Switzerland

15:10
Afternoon Networking & Refreshment Break

15:40
[Q&A session with speakers for country-specific MA strategy discussion]
Country Specific Pricing and Market Access Strategies that work

  • Working with regulatory bodies
  • Pricing opportunities and strategies
  • Common market access strategy downfalls, and remedies
  • Making local country partnerships work

Moderator: Anh Bourcet, Associate Director, ASPAC Health Economic & Market Access, Orthopedics, Johnson & Johnson, Singapore

Panelist:
Philippines: Enrique A. Tayag,
Assistant Secretary, Office for Policy and Health Systems, Department of Health, Philippines
Malaysia: Nathan Kothandaraman, Lead, Market Access, Johnson & Johnson Sdn Bhd, Malaysia
China: Qing Xi, Head of Government Affairs, Market Access & Communications, Pfizer, China
Indonesia: Farida Malawi, Head of Public Sales and New Channels, Vaccine Policy & Advocacy and Market Access, Sanofi Pasteur, Indonesia

16:20
Chairperson’s Summary and End of Main Conference

 

*Session outline may change to accommodate market-specific or company development.